PROMIS NEUROSCIENCES

PMN
Delayed Quote. Delayed  - 01/22 03:59:52 pm
0.11CAD --.--%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
ProMIS Neurosciences Inc, formerly Amorfix Life Sciences Ltd, is a Canada-based development-stage biotech company. The Company discovers and develops precision therapeutics with companion diagnostics for early detection and treatment of neurodegenerative diseases, in particular Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). The assays are developed using its technologies, Epitope Protection and AMFIA. It is developing therapies targeting misfolded, neurotoxic forms of Amyloid beta in AD and superoxide dismutase 1 (SOD1) in ALS. The Company focuses to use its platform to discover further targets for precision medicine solutions through identification of target epitopes on other misfolded strains of Amyloid beta. The Company focuses to evaluate targets on misfolded strains of tau, another protein implicated in neurodegenerative diseases, including Alzheimer's. The Company has not generated any product revenues.
Sales per Business
20182019
CAD
(in Million)
%CAD
(in Million)
%
Precision Medicine Solutions 0.000100% 0.001100%
Sales per region
20182019
CAD
(in Million)
%CAD
(in Million)
%
Canada 0.000100% 0.001100%
Managers
Name Title
Elliot Goldstein President, Chief Executive Officer & Director
Eugene Williams Executive Chairman
Daniel E. Geffken Chief Financial Officer
Neil R. Cashman Director & Chief Scientific Officer
Johannes Minho Roth Independent Director
William W. Wyman Independent Director
Patrick D. Kirwin Independent Director
Richard J. Gregory Independent Director
Anthony J. Giovinazzo Independent Director
Steven Plotkin Chief Physics Officer
Shareholders
Name Equities %
Eugene Williams 7,795,483 2.69%
Elliot Goldstein 7,199,566 2.48%
Neil R. Cashman 5,822,311 2.01%
William W. Wyman 3,503,333 1.21%
Patrick D. Kirwin 2,459,850 0.85%
Anthony J. Giovinazzo 1,285,000 0.44%
Boston Private Wealth LLC 189,710 0.065%
F.L. Putnam Investment Management Co. 189,710 0.065%
J. M. Forbes & Co. LLP 73,500 0.025%
David Wendell Associates, Inc. 60,000 0.021%
Company contact information
ProMIS Neurosciences, Inc.
1920 Yonge Street
Suite 200
Toronto, ON M4S 3E2

Phone : +1.416.847.6898
Fax : +1.416.847.6899
Web : http://www.promisneurosciences.com
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
PROMIS NEUROSCIENCES, INC.10.00%25
GILEAD SCIENCES, INC.14.90%83 911
WUXI APPTEC CO., LTD.30.64%66 044
VERTEX PHARMACEUTICALS0.53%61 782
REGENERON PHARMACEUTICALS11.32%56 760
BEIGENE, LTD.44.94%34 148
GENMAB A/S7.31%28 292
BIONTECH SE33.02%26 111
ARGENX SE5.21%14 672
HUALAN BIOLOGICAL ENGINEERING INC.21.69%14 468
MYOKARDIA, INC.0.00%11 993
NEUROCRINE BIOSCIENCES, INC.19.98%10 923
MIRATI THERAPEUTICS, INC.-2.36%10 783
DENALI THERAPEUTICS INC.-5.53%9 489
ULTRAGENYX PHARMACEUTICAL INC.1.47%9 293
FATE THERAPEUTICS, INC.6.88%8 909
ASCENDIS PHARMA A/S-3.67%8 677
ARROWHEAD PHARMACEUTICALS, INC.6.96%8 433
KODIAK SCIENCES INC.11.86%8 277
SAREPTA THERAPEUTICS, INC.-42.38%7 752
ACCELERON PHARMA INC.-2.60%7 508